Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/4805
Title: | Benefits of low dose immunoglobulin in the treatment of refractory CAPD peritonitis and longevity of technical survival on CAPD | Authors: | Dursun, Belda Tuncer, M. Felek, R. Ersoy, F.F. |
Keywords: | CAPD Immunoglobulin treatment Long term results Morbidity Peritonitis amikacin antibiotic agent immunoglobulin G rifampicin sultamicillin vancomycin adult aged article clinical article continuous ambulatory peritoneal dialysis drug cost drug efficacy female hemodialysis host resistance human kidney failure kidney transplantation long term care longevity low drug dose male peritonitis recurrent disease survival time treatment outcome ultrafiltration Adult Aged Aged, 80 and over Female Humans Immunoglobulins, Intravenous Immunologic Factors Male Middle Aged Peritoneal Dialysis, Continuous Ambulatory Renal Dialysis Retrospective Studies |
Abstract: | In this study we investigated the long term results of intraperitoneal immunoglobulin (Ig) treatment in continuous ambulatory peritoneal dialyses (CAPD) patients with refractory or relapsing peritonitis. Sixteen CAPD patients (4 female, 12 male) with a mean age of 53 ± 11 years (40-80), with a mean CAPD duration of 46.2 ± 4.8 months (17-75) were included in the study. The patients included had a diagnosis of either refractory or relapsing peritonitis unresponsive to appropriate antibiotic therapy. 0.5 g of Ig was added to every exchange bag qid as an adjunctive therapy to the culture based antibiotherapy for 7 days. Intraperitoneal Ig treatment was found to be successful in treating peritonitis in all but one patient. Interestingly, following Ig treatment, long term peritonitis rate decreased significantly compared to the period before treatment (before: 2.2 ± 0.6 episodes/patient/ year vs. after: 0.6 ± 0.17 episodes/patient/year; P = 0.019). The mean CAPD duration after Ig treatment was 30.5 ± 5.4 (4-64) months. Out of 16 patients, one patient who was unresponsive, had his catheter removed and was switched to hemodialysis, and four patients with preexisting ultrafiltration failure or inadequate dialysis problems were transferred to hemodialysis after successful treatment of their peritonitis, one patient was transplanted and 10 patients continued on CAPD. We conclude that low dose Ig treatment may be beneficial in the treatment of refractory or relapsing CAPD peritonitis possibly through restoring impaired host defense within peritoneal cavity. This therapy, by preventing further peritonitis attacks, may prolong survival on CAPD. © Springer 2005. | URI: | https://hdl.handle.net/11499/4805 https://doi.org/10.1007/s11255-004-0009-z |
ISSN: | 0301-1623 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
6
checked on Dec 14, 2024
WEB OF SCIENCETM
Citations
5
checked on Dec 20, 2024
Page view(s)
42
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.